Clinical Trial Finder

Inclusion Criteria:

• - 18 years of age or older.

• - Irresectable stage III or metastatic melanoma.

• - Treated with at least one dose of first-line ipilimumab-nivolumab and considered to be a candidate for maintenance treatment with nivolumab: - previous systemic treatment, including immune-checkpoint inhibitors, in (neo)adjuvant setting for resectable melanoma is allowed.

• - in this protocol, nivolumab maintenance is interchangeable with pembrolizumab maintenance therapy.

• - Response evaluation according to RECIST v1.1 30 using a diagnostic CT documenting target lesions every 12 (-2/+6) weeks from the start of ipilimumab-nivolumab: - for patients with CR on a diagnostic CT at response evaluation, a low-dose CT (which is usually part of 18FDG-PET/CT) is allowed at baseline.

• - for patients with PR on a diagnostic CT at response evaluation, a low-dose CT (which is usually part of 18FDG-PET/CT) is allowed if sufficient target lesions are measurable for response evaluation according to RECIST v1.1 criteria 30.

• - in case of asymptomatic brain metastases prior to start of first-line ipilimumab-nivolumab, intracerebral tumor response should be confirmed using an MRI for response evaluation prior to inclusion in this study.

• - Patients should be included after first CR/PR or first confirmed CR/PR according to RECIST v1.1 30: - inclusion should take place no later than 5 weeks after first confirmed CR/PR.

• - in case of SD at first response evaluation, confirmed CR/PR is required for inclusion.

• - planned and willing to discontinue nivolumab within 4(+1) weeks after inclusion, i.e. first CR/PR or first confirmed CR/PR.

• - no later than 9 months after start of treatment with ipilimumab-nivolumab.

• - Presence of MRI brain for the screening of brain metastases (prior to discontinuation of ipilimumab-nivolumab) - Participants with previously locally treated brain metastases may participate in case they meet the following criteria: - completely asymptomatic brain metastases at inclusion.

• - MRI of brain at baseline and for response evaluation during treatment.

• - Signed and dated informed consent form.

Exclusion Criteria:

• - Patients with SD/PD according to RECIST v1.1.

• - Malignant disease other than being treated in this study.

Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to start of study treatment; completely resected basal cell and squamous cell skin cancers and any completely resected carcinoma in situ.

• - Presence of symptomatic brain metastases: - prior to first-line treatment with ipilimumab-nivolumab, or; - when defined as new or progressive brain metastases at the time of study entry; - brain metastases with need for steroid treatment in the last 8 weeks prior to study entry Note: An incidental epileptic seizure caused by a brain lesion is not considered an exclusion criterion.

(provided that the other in- and exclusion criteria are met);

• - Presence of leptomeningeal metastases; - Systemic chronic steroid therapy (>10mg/day prednisone or equivalent) at inclusion or patients who need or needed any other second-line immunosuppressive therapy (e.g. infliximab, mycophenolate mofetil) for the treatment of immune related adverse events (irAEs).

Note: local steroids such as topical, inhaled, nasal and ophthalmic steroids are allowed. - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

Arms

Experimental: Early discontinuation of nivolumab

Interventions

Drug: - nivolumab

Early discontinuation of nivolumab maintenance therapy in patients with irresectable stage III or metastatic melanoma